Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (Q43041133)

12 November 2017

Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (English)

1 reference

12 November 2017

4

1 reference

12 November 2017

7

Stefan Zeuzem

1 reference

12 November 2017

8

Michael P Manns

1 reference

12 November 2017

1

Markus Cornberg

1 reference

12 November 2017

2

Holger Hinrichsen

1 reference

12 November 2017

Gerlinde Teuber

3

1 reference

PubMed ID

12445427

12 November 2017

Uta Naumann

series ordinal

5

1 reference

PubMed ID

12445427

12 November 2017

Christian Falkenberg

series ordinal

6

1 reference

12 November 2017

1 December 2002

1 reference

12 November 2017

Journal of Hepatology

1 reference

12 November 2017

37

1 reference

12 November 2017

6

1 reference

12 November 2017

843-847

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Combination therapy of chronic hepatitis C: an important step but not the final goal!

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Treatment of chronic hepatitis C virus infection in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Inhibitors of inosinate dehydrogenase activity in ehrlich ascites tumor cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Mechanism of action of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Mycophenolate mofetil and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900300-8

7 January 2021

10.1016/S0168-8278(02)00300-8

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

12445427